BANCA MEDIOLANUM SPA (BMED.MI) Stock Fundamental Analysis
BIT:BMED - Euronext Milan - IT0004776628 - Common Stock - Currency: EUR
BMED gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 50 industry peers in the Financial Services industry. There are concerns on the financial health of BMED while its profitability can be described as average. BMED has a correct valuation and a medium growth rate. Finally BMED also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
BMED had positive earnings in the past year.
BMED had a positive operating cash flow in the past year.
Each year in the past 5 years BMED has been profitable.
The reported operating cash flow has been mixed in the past 5 years: BMED reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of BMED (1.82%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of 38.86%, BMED belongs to the top of the industry, outperforming 90.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.82% | ||
| ROE | 38.86% | ||
| ROIC | N/A |
ROA(3y)1.24%
ROA(5y)1.08%
ROE(3y)27.98%
ROE(5y)24.91%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Profit Margin value of 16.26%, BMED is doing good in the industry, outperforming 62.00% of the companies in the same industry.
BMED's Profit Margin has improved in the last couple of years.
The Operating Margin and Gross Margin are not available for BMED so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 16.26% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y16.85%
PM growth 5Y14.52%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BMED does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BMED has less shares outstanding
The number of shares outstanding for BMED has been increased compared to 5 years ago.
BMED has a better debt/assets ratio than last year.
2.2 Solvency
BMED has a debt to FCF ratio of 6.56. This is a slightly negative value and a sign of low solvency as BMED would need 6.56 years to pay back of all of its debts.
BMED's Debt to FCF ratio of 6.56 is in line compared to the rest of the industry. BMED outperforms 52.00% of its industry peers.
A Debt/Equity ratio of 1.79 is on the high side and indicates that BMED has dependencies on debt financing.
BMED has a Debt to Equity ratio of 1.79. This is in the lower half of the industry: BMED underperforms 70.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.79 | ||
| Debt/FCF | 6.56 | ||
| Altman-Z | N/A |
ROIC/WACCN/A
WACC7.69%
2.3 Liquidity
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | N/A | ||
| Quick Ratio | N/A |
3. Growth
3.1 Past
BMED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.00%, which is quite impressive.
The Earnings Per Share has been growing by 14.21% on average over the past years. This is quite good.
BMED shows a strong growth in Revenue. In the last year, the Revenue has grown by 44.99%.
The Revenue has been growing slightly by 0.11% on average over the past years.
EPS 1Y (TTM)36%
EPS 3Y15.94%
EPS 5Y14.21%
EPS Q2Q%81.82%
Revenue 1Y (TTM)44.99%
Revenue growth 3Y-0.53%
Revenue growth 5Y0.11%
Sales Q2Q%11.52%
3.2 Future
The Earnings Per Share is expected to decrease by -4.80% on average over the next years.
Based on estimates for the next years, BMED will show a small growth in Revenue. The Revenue will grow by 1.26% on average per year.
EPS Next Y-19.14%
EPS Next 2Y-8.65%
EPS Next 3Y-4.8%
EPS Next 5YN/A
Revenue Next Year-4.82%
Revenue Next 2Y1.08%
Revenue Next 3Y1.26%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 10.00, the valuation of BMED can be described as reasonable.
Compared to the rest of the industry, the Price/Earnings ratio of BMED indicates a somewhat cheap valuation: BMED is cheaper than 72.00% of the companies listed in the same industry.
BMED is valuated cheaply when we compare the Price/Earnings ratio to 28.04, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 12.40, the valuation of BMED can be described as correct.
BMED's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. BMED is cheaper than 64.00% of the companies in the same industry.
BMED's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 37.64.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10 | ||
| Fwd PE | 12.4 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, BMED is valued a bit cheaper than the industry average as 76.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.2 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as BMED's earnings are expected to decrease with -4.80% in the coming years.
PEG (NY)N/A
PEG (5Y)0.7
EPS Next 2Y-8.65%
EPS Next 3Y-4.8%
5. Dividend
5.1 Amount
BMED has a Yearly Dividend Yield of 6.76%, which is a nice return.
BMED's Dividend Yield is rather good when compared to the industry average which is at 3.62. BMED pays more dividend than 94.00% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.35, BMED pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 6.76% |
5.2 History
On average, the dividend of BMED grows each year by 14.04%, which is quite nice.
Dividend Growth(5Y)14.04%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
BMED pays out 37.38% of its income as dividend. This is a sustainable payout ratio.
DP37.38%
EPS Next 2Y-8.65%
EPS Next 3Y-4.8%
BIT:BMED (7/25/2025, 7:00:00 PM)
15
-0.07 (-0.46%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryFinancial Services
Earnings (Last)
Earnings (Next)
Inst Owners10.45%
Inst Owner ChangeN/A
Ins Owners40.28%
Ins Owner ChangeN/A
Market Cap11.18B
Analysts82.5
Price Target15.93 (6.2%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 6.76% |
Yearly Dividend0.79
Dividend Growth(5Y)14.04%
DP37.38%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.19%
Min EPS beat(2)1.77%
Max EPS beat(2)42.6%
EPS beat(4)3
Avg EPS beat(4)10.87%
Min EPS beat(4)-1.3%
Max EPS beat(4)42.6%
EPS beat(8)6
Avg EPS beat(8)7.49%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-32.79%
Min Revenue beat(2)-44.68%
Max Revenue beat(2)-20.91%
Revenue beat(4)0
Avg Revenue beat(4)-25.64%
Min Revenue beat(4)-44.68%
Max Revenue beat(4)-12.99%
Revenue beat(8)0
Avg Revenue beat(8)-20.01%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.06%
PT rev (3m)3.86%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.72%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10 | ||
| Fwd PE | 12.4 | ||
| P/S | 1.16 | ||
| P/FCF | 10.2 | ||
| P/OCF | 9.7 | ||
| P/B | 2.78 | ||
| P/tB | 2.93 | ||
| EV/EBITDA | N/A |
EPS(TTM)1.5
EY10%
EPS(NY)1.21
Fwd EY8.06%
FCF(TTM)1.47
FCFY9.8%
OCF(TTM)1.55
OCFY10.31%
SpS12.91
BVpS5.4
TBVpS5.12
PEG (NY)N/A
PEG (5Y)0.7
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.82% | ||
| ROE | 38.86% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 16.26% | ||
| GM | N/A | ||
| FCFM | 11.39% |
ROA(3y)1.24%
ROA(5y)1.08%
ROE(3y)27.98%
ROE(5y)24.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y16.85%
PM growth 5Y14.52%
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.79 | ||
| Debt/FCF | 6.56 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 95.34% | ||
| Cap/Sales | 0.59% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 70.03% | ||
| Current Ratio | N/A | ||
| Quick Ratio | N/A | ||
| Altman-Z | N/A |
F-Score7
WACC7.69%
ROIC/WACCN/A
Cap/Depr(3y)87.43%
Cap/Depr(5y)95.87%
Cap/Sales(3y)2.01%
Cap/Sales(5y)1.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36%
EPS 3Y15.94%
EPS 5Y14.21%
EPS Q2Q%81.82%
EPS Next Y-19.14%
EPS Next 2Y-8.65%
EPS Next 3Y-4.8%
EPS Next 5YN/A
Revenue 1Y (TTM)44.99%
Revenue growth 3Y-0.53%
Revenue growth 5Y0.11%
Sales Q2Q%11.52%
Revenue Next Year-4.82%
Revenue Next 2Y1.08%
Revenue Next 3Y1.26%
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y160.66%
FCF growth 3Y8.9%
FCF growth 5Y27.28%
OCF growth 1Y165.69%
OCF growth 3Y8.21%
OCF growth 5Y25.97%